FibroBiologics, Inc.
FibroBiologics, Inc. is a clinical-stage biotechnology company developing fibroblast-based cell therapies for chronic diseases with high unmet medical need. Its pipeline includes CYWC628, CYPS317, CYMS101 and CybroCell™, with programs aimed at wound healing, autoimmune disease, degenerative disc disease, psoriasis, certain cancers and potential longevity applications.
Fiscal year 2025 · change from previous year
Development 2022–2025
Business
Share of revenueClinical and preclinical fibroblast-based therapies targeting specific diseases such as diabetic foot ulcers, psoriasis and MS.
The underlying fibroblast cell platform and related intellectual property used to generate multiple product candidates.
Internal discovery, preclinical studies, clinical trial preparation and regulatory work for the pipeline.
Customers
FibroBiologics does not yet sell commercial products; its near-term 'customers' are clinical trial participants, investigators, CDMOs and regulators that enable development. If approved, its therapies would be sold to healthcare providers, hospitals and specialty treatment centers serving patients with chronic diseases and difficult-to-heal conditions.
Patients, investigators, CROs and CDMOs involved in running preclinical work and clinical trials for the pipeline.
Hospitals and wound-care clinics that would use CYWC628 if approved for diabetic foot ulcers and related wounds.
Dermatologists, neurologists and other specialists who could prescribe future approved therapies for psoriasis or MS.
FDA and other agencies that must clear INDs and approve trials and eventual commercialization.
Strategy
FibroBiologics is focused on advancing its fibroblast platform through clinical proof-of-concept, starting with CYWC628 and expanding into additional indications. Near term, the company is prioritizing manufacturing readiness, trial execution and IP protection while relying on external capital and strategic collaborations to fund development.
A successful diabetic foot ulcer trial would validate the platform and de-risk later programs.
Cell therapy supply depends on reliable CDMO execution and sterility/process control.
Multiple indications improve the odds that at least one program reaches commercialization.
The company has no product revenue and needs external funding to continue development.
Geography
The company is headquartered in the United States and conducts most corporate, R&D and financing activity there. Its disclosed clinical development footprint is international, with a planned CYWC628 Phase 1/2 trial in Australia and FDA interactions in the United States.
Risks
The company is pre-revenue, has a limited operating history and depends on successful clinical development, regulatory approval and financing to continue as a going concern. Its biggest execution risks are manufacturing complexity, sterility/process failures, clinical setbacks and the possibility that larger biotech and pharma competitors reach the market first.
- Going concern and funding riskImpact: CriticalLikelihood: High
The company has incurred losses since inception and needs substantial additional capital to fund trials and operations.
Exposure: All development programs
- Manufacturing and sterility riskImpact: HighLikelihood: High
Cell therapy production requires tight process control; the company already experienced timeline extensions from process issues.
Exposure: CYWC628 and future cell therapy supply
- Clinical development riskImpact: HighLikelihood: High
Programs may fail to show safety or efficacy, which would prevent approval and commercialization.
Exposure - Competitive displacementImpact: HighLikelihood: Medium
Large pharma and biotech firms have greater resources and may commercialize competing therapies first.
Exposure: All target indications
- Commercialization capability gapImpact: MediumLikelihood: Medium
The company has no sales force or distribution network and would need partners or new capabilities post-approval.
Exposure: Future approved products
Accounting
Judgemental itemsClinical, preclinical and manufacturing costs are expensed as incurred, making losses sensitive to trial timing.
Impact: Quarterly operating loss volatility
Advance payments for CRO/CDMO services are recorded as prepaid assets and expensed later.
Impact: Timing of expense recognition
As a development-stage biotech, equity awards can be a meaningful part of employee cost.
Impact: Operating expense and net loss
Office and lab rent create fixed obligations that affect liquidity and disclosed commitments.
Impact: Cash burn and contractual obligations
Similar listed companies
Publicly listed companies with a comparable business focus.
Forte Biosciences, Inc.
Pharmaceutical Preparations
Mesoblast Limited
MESO · Biological Products, (No Diagnostic Substances)
Mesoblast Ltd is a biopharmaceutical company focused on developing and commercializing allogeneic cell therapies based on mesenchymal stromal cells.
Celularity Inc
CELU · Pharmaceutical Preparations
Tyra Biosciences, Inc.
TYRA · Pharmaceutical Preparations
Kairos Pharma, LTD.
KAPA · Pharmaceutical Preparations
Ocean Biomedical, Inc.
OCEA · Pharmaceutical Preparations
Last updated: 24/09/2026